Many academic scientists find news about industry research hard to find. It travels by word of mouth, formal publications appear late, if ever. This is true of γ-secretase inhibitors, which for a while were prime candidates for the next generation of AD drugs. Then, additional targets for this complex enzyme were discovered and rumors about side effects cast doubt over this therapeutic strategy. So it was noteworthy that Eric Parker from the Schering-Plough Research Institute in Kenilworth, New Jersey, reported at the Society for Neuroscience meeting in New Orleans what many may have heard already: At least some γ-secretase inhibitors cause mechanism-based side effects so severe as to disqualify them from clinical testing.

Parker reported on experiments with a potent γ-secretase inhibitor that also inhibits Notch cleavage (LY-411,575), and a less potent stereoisomer to serve as a control (133.11). The work was conducted in large part by Gwen Wong, who is now at ALS-TDF. The researchers fed LY-411,575 for 15 days to wild-type mice and CRND8 APP transgenics, then they measured plasma and brain Aβ levels, studied effects on the immune system by flow cytometry, and examined tissues histologically.

As expected, LY-411,575 decreased plasma and brain Aβ levels. However, at the concentrations where it did so, it also increased the size of certain immature thymocyte and B lymphocyte populations while reducing the number of mature T cells in the thymus and mature B cells in spleen and blood. Specifically, LY-411,575 blocked the physiological transition of certain double-negative (CD4-CD8-) populations of immature lymphocytes (e.g., the Cd44+/25+ set) to their single-positive, differentiated state (e.g., the CD44+/25- set). What’s more, the normal cellular architecture of the mice’s intestinal villi looked abnormal, and the mucosa showed goblet cell hyperplasia. At the higher inhibitor doses tested, the mice lost weight and died, probably due to the intestinal side effects, Parker said. The histology of the brain, liver, kidney, lung, heart, adrenal gland, bone marrow and stomach appeared normal. The T cell effects predictably resulted from inhibition of Notch cleavage, as Notch is known to function in thymocyte development, but the B cell and intestinal effects were unexpected, Parker added.

These results still leave open the possibility of inhibiting γ-secretase with other inhibitors that distinguish between APP and Notch. Alas, recent reports suggest that’s easier said than done, at least with classic strategies of fitting competitive inhibitors into the enzyme’s catalytic pocket. Researchers at Merck, Sharpe and Dohm in Harlow, United Kingdom, reported this summer that a range of such inhibitors drawn from six different compound classes were all unable to distinguish clearly between APP and Notch in vitro (Lewis et al., 2003; see also Shearman section in ARF related news story). Others have reported that γ-secretase inhibitors cause developmental defects consistent with Notch inhibition in fruit flies (Micchelli et al., 2002) and zebra fish (Geling et al., 2002). For a review, see Tsai et al., 2002).

At the same time, however, a flurry of meeting presentations on NSAIDs is pointing to a new way of achieving this goal. These studies explore in more detail the mechanism by which certain NSAIDs inhibit γ-secretase in non-competitive ways. At this point, results vary depending on the assay, dose, and compounds used, and some data contradict each other. Overall, however, the new hope is that an existing NSAID can be found—or, more likely perhaps, a new one designed—that tweaks γ-secretase allosterically, i.e., outside of the active site. It would have to do so in such a way that APP cleavage shifts away from generating Aβ42 and toward Aβ38 (which by all accounts so far is safe to have in increased amounts), while leaving alone proteolysis of Notch and other targets, such as ErbB-4. For more detail, view abstracts 295.2, 295.7, 295.21, 295.22, 336.8, 336.9, 523.3, 549.4, 729.1, and 876.14 at the SfN/ScholarOne website.—Gabrielle Strobel.

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

  1. A mechanism to inhibit partially PS1 expression without modifying Notch activity has been postulated in our recent paper in FEBS Letters. It should be noted that the compound used is physiologically produced in the right amount in young people and strongly reduced in the elderly. We would like to see our paper considered in the course of this discussion.

    References:
    Scarpa S. et al. FEBS Lett 2003;541:145-148. Abstract

Comments on Primary Papers for this Article

No Available Comments on Primary Papers for this Article

References

News Citations

  1. Philipp Kahle and Bart De Strooper Report from Lake Titisee, Germany: Part III

Paper Citations

  1. . Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages. Biochemistry. 2003 Jun 24;42(24):7580-6. PubMed.
  2. . Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J. 2003 Jan;17(1):79-81. PubMed.
  3. . A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep. 2002 Jul;3(7):688-94. PubMed.
  4. . The search for gamma-secretase and development of inhibitors. Curr Med Chem. 2002 Jun;9(11):1087-106. PubMed.

Other Citations

  1. CRND8 APP transgenics

External Citations

  1. ALS-TDF
  2. SfN/ScholarOne

Further Reading

Papers

  1. . Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004 Mar 26;279(13):12876-82. PubMed.

Primary Papers

  1. . Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004 Mar 26;279(13):12876-82. PubMed.